Filtered By:
Condition: Heart Failure
Drug: Pradaxa

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 109 results found since Jan 2013.

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients Clinical Sciences
Conclusions— All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin. Our model showed that apixaban was the most effective anticoagulant in a general atrial fibrillation population and has an incremental cost-effectiveness ratio <$50 000/QALY. For those with higher stroke risk (CHADS2≥3), dabigatran was the most cost-effective treatment option.
Source: Stroke - May 22, 2016 Category: Neurology Authors: Shah, A., Shewale, A., Hayes, C. J., Martin, B. C. Tags: Anticoagulants, Cost-Effectiveness, Ischemic Stroke Clinical Sciences Source Type: research

Special MRI scan could identify stroke risk in people with atrial fibrillation
Atrial fibrillation is a heart rhythm disorder that affects millions of people. It can make you feel lousy. Even worse, it can cause potentially disabling or deadly strokes. A special MRI scan may — I stress the “may” — help identify people with atrial fibrillation who are at high risk of having a stroke. This could help many people with this condition to avoid taking warfarin or other clot-preventing medications for life. A normal heartbeat starts in a cluster of cells called the pacemaker. It sits in the heart’s upper right chamber (the right atrium). These cells generate a pulse of electricity that...
Source: New Harvard Health Information - April 28, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Heart Health atrial fibrillation MRI prevention special MRI scan Stroke Stroke Risk Source Type: news

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation Arrhythmia and Electrophysiology
Conclusions Adherence to anticoagulation is poor in practice and may be modestly improved with NOACs. Adherence to therapy appears to be most important in patients with CHA2DS2-VASc score ≥2, whereas the benefits of anticoagulation may not outweigh the harms in patients with CHA2DS2-VASc score 0 or 1.
Source: JAHA:Journal of the American Heart Association - February 23, 2016 Category: Cardiology Authors: Yao, X., Abraham, N. S., Alexander, G. C., Crown, W., Montori, V. M., Sangaralingham, L. R., Gersh, B. J., Shah, N. D., Noseworthy, P. A. Tags: Arrhythmias, Atrial Fibrillation, Secondary Prevention, Intracranial Hemorrhage, Ischemic Stroke Arrhythmia and Electrophysiology Source Type: research

Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Original Articles
Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Singer, D. E., Mahaffey, K. W., Kowey, P. R., Thomas, L., Go, A. S., Lopes, R. D., Chang, P., Peterson, E. D., Gersh, B. J., on behalf of the ORBIT-AF Investigators Tags: Coumarins, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Risk Factors for Stroke, Anticoagulants Original Articles Source Type: research

Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
CONCLUSIONS: Overall, results of secondary analyses indicate that the recommended dosing strategy for each of the DOACs produces a consistent anticoagulant effect across a diverse patient population, including those at increased risk of stroke or bleeding. PMID: 30081727 [PubMed - in process]
Source: Adv Data - August 9, 2018 Category: Epidemiology Authors: Stacy ZA, Richter SK Tags: Ther Adv Cardiovasc Dis Source Type: research

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.
DISCUSSION: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation. PMID: 24790645 [PubMed - as supplied by publisher]
Source: Adv Data - May 1, 2014 Category: Epidemiology Authors: Tsivgoulis G, Krogias C, Sands KA, Sharma VK, Katsanos AH, Vadikolias K, Papageorgiou SG, Heliopoulos I, Shiue H, Mitsoglou A, Liantinioti C, Athanasiadis D, Giannopoulos S, Piperidou C, Voumvourakis K, Alexandrov AV Tags: Ther Adv Neurol Disord Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Discussion: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Tsivgoulis, G., Krogias, C., Sands, K. A., Sharma, V. K., Katsanos, A. H., Vadikolias, K., Papageorgiou, S. G., Heliopoulos, I., Shiue, H., Mitsoglou, A., Liantinioti, C., Athanasiadis, D., Giannopoulos, S., Piperidou, C., Voumvourakis, K., Alexandrov, A. Tags: Original Research Source Type: research

Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research

Stroke prevention in atrial fibrillation: evidence from real-life studies
Atrial fibrillation (AF) is an increasing public health issue, especially owing to an accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of therapy for stroke prevention in AF. The clinical benefits of vitamin K antagonists (VKAs; namely warfarin) shown in randomized controlled trials (RCTs) have been challenged when used in clinical practice by issues including the need for international normalized ratio (INR) monitoring, food and drug interactions, low time in the therapeutic range in substantial numbers of patients, and serious bleeding events. Combined, these have led to both an under-i...
Source: European Journal of Heart Failure Supplements - July 10, 2015 Category: Cardiology Authors: Akao, M., Beyer-Westendorf, J., Goto, S., Peterson, E. Tags: Articles Source Type: research

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Publication date: September 2018Source: IJC Heart & Vasculature, Volume 20Author(s): Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann ChenAbstractAtrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X...
Source: IJC Heart and Vasculature - September 1, 2018 Category: Cardiology Source Type: research

Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry
CONCLUSION: This registry obtained an important overview of the current safety and effectiveness of the dabigatran etexilate in Turkey. Our results indicate similar rates of thromboembolic and bleeding events with pivotal phase 3 trial and other real-life registries. However, rate of undertreatment usage of dabigatran etexilate in real life was found to be considerable.PMID:34881702 | DOI:10.5543/tkda.2021.07734
Source: Turk Kardiyoloji Dernegi arsivi - December 9, 2021 Category: Cardiology Authors: Cihan Alt ın Caner Topalo ğlu Nurullah Çetin Onur Dalg ıç Veysel Yavuz Emin Alio ğlu Nazile Bilgin Cenk Ekmek çi Nihat Pekel Mehmet Emre Özpelit E şref Tunçer Ebru İpek Türkoğlu Kamil T ülüce Umut Kocaba ş K ıvanç Yüksel U ğur Önsel T Source Type: research